Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alpha1-Antitrypsin Deficiency

Conditions

Alpha1-Antitrypsin Deficiency

Trial Timeline

Aug 13, 2021 → Aug 1, 2025

NCT ID

NCT04722887

About Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)

Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human) is a phase 1/2 stage product being developed by Grifols for Alpha1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT04722887. Target conditions include Alpha1-Antitrypsin Deficiency.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04722887	Phase 1/2	Completed	Aug 13, 2021	Aug 1, 2025	Alpha1-Antitrypsin Deficiency

Competing Products

3 competing products in Alpha1-Antitrypsin Deficiency

See all competitors

Product	Company	Stage	Hype Score
VX-864 + Placebo	Vertex Pharmaceuticals	Phase 2	35
Alpha-1 MP	Grifols	Phase 1/2	29
Alpha-1 MP	Grifols	Phase 1/2	29